Søren Weis Dahl
Director/Board Member at PILA PHARMA AB
Profile
Søren Weis Dahl is currently the Chief Executive Officer & Director at Deck Therapeutics, Inc. and a Director at Pila Pharma AB.
He was previously the Chief Executive Officer at Prophylix AS from 2015 to 2019.
Dahl holds an MBA from Copenhagen Business School, a doctorate from the Technical University of Denmark, and a graduate degree from the same institution.
Søren Weis Dahl active positions
| Companies | Position | Start |
|---|---|---|
| PILA PHARMA AB | Director/Board Member | 30/05/2023 |
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Chief Executive Officer | 01/01/2014 |
Former positions of Søren Weis Dahl
| Companies | Position | End |
|---|---|---|
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Chief Executive Officer | 01/01/2019 |
Training of Søren Weis Dahl
| Copenhagen Business School | Masters Business Admin |
| Technical University of Denmark | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PILA PHARMA AB | Health Technology |
| Private companies | 2 |
|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Health Technology |
- Stock Market
- Insiders
- Søren Weis Dahl
